ATE442439T1 - Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren - Google Patents

Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren

Info

Publication number
ATE442439T1
ATE442439T1 AT96903473T AT96903473T ATE442439T1 AT E442439 T1 ATE442439 T1 AT E442439T1 AT 96903473 T AT96903473 T AT 96903473T AT 96903473 T AT96903473 T AT 96903473T AT E442439 T1 ATE442439 T1 AT E442439T1
Authority
AT
Austria
Prior art keywords
melanoma
antigene
diagnostic
application
therapeutic procedures
Prior art date
Application number
AT96903473T
Other languages
English (en)
Inventor
Paul Robbins
Steven Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE442439T1 publication Critical patent/ATE442439T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96903473T 1995-01-10 1996-01-11 Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren ATE442439T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/370,909 US5843648A (en) 1995-01-10 1995-01-10 P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
PCT/US1996/000473 WO1996021734A2 (en) 1995-01-10 1996-01-11 P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods

Publications (1)

Publication Number Publication Date
ATE442439T1 true ATE442439T1 (de) 2009-09-15

Family

ID=23461684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903473T ATE442439T1 (de) 1995-01-10 1996-01-11 Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren

Country Status (8)

Country Link
US (1) US5843648A (de)
EP (1) EP0871725B1 (de)
JP (1) JP4223072B2 (de)
AT (1) ATE442439T1 (de)
AU (1) AU705992B2 (de)
CA (1) CA2209990A1 (de)
DE (1) DE69638024D1 (de)
WO (1) WO1996021734A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876972A (en) * 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
WO2000071577A1 (en) * 1999-05-25 2000-11-30 Human Genome Sciences, Inc. Meth1 and meth2 polynucleotides and polypeptides
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
AU2001252998A1 (en) * 2000-03-28 2001-10-08 University Of Rochester Methods of producing a library and methods of selecting polynucletides
EP2848255B1 (de) * 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Eine nicht-natürlich vorkommende, Drosophila-basierte antigen-präsentierende Zelle zur Herstellung einer CD8-Zellsuspension zur Verwendung bei der Krebsbehandlung
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US6951720B2 (en) * 2001-05-10 2005-10-04 San Diego State University Foundation Use of phosphorothiolate polynucleotides in ligating nucleic acids
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
PT1526187E (pt) * 2003-05-01 2008-10-16 Veridex Llc Ensaios de gânglios linfáticos intra-operatórios
US8604166B2 (en) 2008-09-02 2013-12-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Melanoma antigen peptide and uses thereof
WO2010028672A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100310591A1 (en) * 2009-01-28 2010-12-09 Robert Humphreys Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5134227A (en) * 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1993014189A1 (en) * 1992-01-21 1993-07-22 Ludwig Institute For Cancer Research Method for determining cytolytic t cell precursors
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
PT687180E (pt) * 1992-12-22 2001-04-30 Ludwig Inst Cancer Res Metodos para a deteccao e o tratamento de individuos tendo celulas anormais que expressam antigenios do peptido hla-a2/tirosinase
WO1994023067A1 (en) * 1993-03-31 1994-10-13 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
ATE272113T1 (de) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma

Also Published As

Publication number Publication date
WO1996021734A3 (en) 1996-11-28
EP0871725A2 (de) 1998-10-21
AU705992B2 (en) 1999-06-03
US5843648A (en) 1998-12-01
EP0871725B1 (de) 2009-09-09
DE69638024D1 (de) 2009-10-22
AU4755496A (en) 1996-07-31
JPH11502405A (ja) 1999-03-02
WO1996021734A2 (en) 1996-07-18
JP4223072B2 (ja) 2009-02-12
CA2209990A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
EP1630229A3 (de) Melanoma Antigene
EP2311952A3 (de) Antikörper gegen MART-1 Protein oder Fragmenten davon
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
TR199801722T2 (xx) Peptit imm�nojenler.
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EP2261358A3 (de) Streptokokken-Antigene
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE69028388D1 (de) Monoklonaler antikörper gegen ein neues humanes tumor assoziiertes antigen
GR1000477B (el) Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους.
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
ATE298798T1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
BG101024A (bg) Моноклонално антитяло срещу сd44v6
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
BR9106303A (pt) Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla
DK0610335T3 (da) Fremgangsmåder til udformning af rekombitope peptider
RU94046414A (ru) Моноклональные антитела к гликопротеину р, их получение и применение, продуцирующие их клетки, иммунологический диагностический набор на их основе, терапевтический состав
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE265533T1 (de) Saeugetierchemokine
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties